Literature DB >> 13768300

Cyclophosphamide in Hodgkin's disease and related disorders.

J Q MATTHIAS, J J MISIEWICZ, R B SCOTT.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS/therapy; HODGKIN'S DISEASE/therapy

Mesh：

Substances：

Year:  1960        PMID： 13768300      PMCID： PMC2098561          DOI： 10.1136/bmj.2.5216.1837

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  9 in total

1.  [Clinical experiences with rest nitrogen phosphamide esters in hemopathies].

Authors:  G BRICHTA; J KUHBOCK; E E REIMER
Journal:  Wien Z Inn Med       Date:  1958-07

2.  [Preliminary report on the therapy of maligant tumors with a new N-lost-phosphamidester].

Authors:  E BAUMANN
Journal:  Medizinische       Date:  1959-04-04

3.  Immediate and remote results of chloroethylamine treatment of Hodgkin's disease.

Authors:  L F LARIONOV
Journal:  Br Med J       Date:  1956-02-04

4.  [First experience in treating malignant tumors with a new nitrogen mustard-phosphamidester].

Authors:  R GROSS; K LAMBERS
Journal:  Dtsch Med Wochenschr       Date:  1958-03-21       Impact factor: 0.628

5.  [Pharmacological characterization of cyclic nitrogen mustard phosphamide esters as cancer therapeutic agents].

Authors:  N BROCK
Journal:  Arzneimittelforschung       Date:  1958-01

6.  The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides.

Authors:  A Gilman; F S Philips
Journal:  Science       Date:  1946-04-05       Impact factor: 47.728

7.  [Effect of a cyclic nitrogen mustard-phosphamidester on experimentally induced tumors in rats; chemotherapeutic effect and pharmacological properties of B 518 ASTA].

Authors:  N BROCK; H WILMANNS
Journal:  Dtsch Med Wochenschr       Date:  1958-03-21       Impact factor: 0.628

8.  Some effects of cyclophosphamide (cytoxan) on normal mice and mice with L1210 leukemia.

Authors:  M LANE
Journal:  J Natl Cancer Inst       Date:  1959-12       Impact factor: 13.506

9.  Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat.

Authors:  H ARNOLD; F BOURSEAUX; N BROCK
Journal:  Nature       Date:  1958-03-29       Impact factor: 49.962
  9 in total
  10 in total

1.  MELPHALAN IN THE TREATMENT OF MYELOMATOSIS.

Authors:  D E SPEED; D A GALTON; A SWAN
Journal:  Br Med J       Date:  1964-06-27

2.  [The clinical picture of cervical lymph node diseases].

Authors:  W BECKER
Journal:  Arch Ohren Nasen Kehlkopfheilkd       Date:  1963

3.  Cyclophosphamide in treatment of disseminated malignant disease.

Authors:  C J ANDERS; N H KEMP
Journal:  Br Med J       Date:  1961-12-09

4.  Clinical experience with cyclophosphamide in malignant disease.

Authors:  D A DICK; A F PHILLIPS
Journal:  Can Med Assoc J       Date:  1961-10-28       Impact factor: 8.262

5.  Chemotherapy of malignant disease: a review of theory and practice.

Authors:  G D HART
Journal:  Can Med Assoc J       Date:  1962-03-31       Impact factor: 8.262

6.  Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine.

Authors:  G H Fairley; M J Patterson; R B Scott
Journal:  Br Med J       Date:  1966-07-09

7.  Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

Authors:  Jitakshi De; Robert E Brown
Journal:  Int J Clin Exp Med       Date:  2010-01-30

Review 8.  Cancer chemotherapy--the first twenty-five years.

Authors:  R B Scott
Journal:  Br Med J       Date:  1970-10-31

9.  Cyclophosphamide in the treatment of myelomatosis.

Authors:  O S Choi; A English; J H Hilton; G E Catton; M D Brown
Journal:  Can Med Assoc J       Date:  1967-11-04       Impact factor: 8.262

Review 10.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.